Quarterly report pursuant to Section 13 or 15(d)

LICENSES ACQUIRED (Details)

v3.23.1
LICENSES ACQUIRED (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Mar. 31, 2021
Jun. 30, 2021
Mar. 31, 2021
Jul. 31, 2020
Mar. 31, 2023
Mar. 31, 2022
LICENSES/PRODUCTS ACQUIRED            
Payments to Acquire Productive Assets         $ 5,000 $ 20,000
D F D Agreement | Minimum            
LICENSES/PRODUCTS ACQUIRED            
Percentage of royalties payable on net sales   10.00%        
D F D Agreement | Maximum            
LICENSES/PRODUCTS ACQUIRED            
Threshold additional contingent regulatory and commercial milestone payments payable   $ 158,000        
Percentage of royalties payable on net sales   15.00%        
Asset purchase agreement | Qbrexza            
LICENSES/PRODUCTS ACQUIRED            
Age of patients 9 years          
Percentage of diminution in royalty     50.00%      
Asset purchase agreement | Royalty payment percentage for first two years | Qbrexza            
LICENSES/PRODUCTS ACQUIRED            
Period of royalty payments 2 years          
Asset purchase agreement | Royalty payment percentage for eight years thereafter | Qbrexza            
LICENSES/PRODUCTS ACQUIRED            
Term of royalty     8 years      
Asset purchase agreement | Minimum | Royalty payment percentage for first two years | Qbrexza            
LICENSES/PRODUCTS ACQUIRED            
Percent of royalty payments     30.00%      
Asset purchase agreement | Minimum | Royalty payment percentage for eight years thereafter | Qbrexza            
LICENSES/PRODUCTS ACQUIRED            
Percent of royalty payments     12.00%      
Asset purchase agreement | Maximum | Royalty payment percentage for first two years | Qbrexza            
LICENSES/PRODUCTS ACQUIRED            
Percent of royalty payments     40.00%      
Asset purchase agreement | Maximum | Royalty payment percentage for eight years thereafter | Qbrexza            
LICENSES/PRODUCTS ACQUIRED            
Percent of royalty payments     19.00%      
Asset purchase agreement | Eli Lilly and Company | Qbrexza            
LICENSES/PRODUCTS ACQUIRED            
Upfront fees     $ 12,500      
Milestone payments payable $ 144,000   $ 144,000      
License and supply agreement With DRL | Accutane            
LICENSES/PRODUCTS ACQUIRED            
Threshold additional contingent regulatory and commercial milestone payments payable       $ 3,000    
Upfront fees       1,000    
Milestone payments payable       4,000    
Amount of expense agreed to pay under the agreement       5,000    
Contingent amount payable       $ 17,000    
Renewable Mutual Agreement Term       10 years    
Termination Written Notice Period To Other Party       180 days